益普生公布2025年前三季度销售额

Core Insights - The company reported strong sales growth for the first nine months of 2025, prompting an upward revision of its full-year financial guidance [1][2] - The CEO highlighted robust performance across three therapeutic areas, with increasing contributions from the rare liver disease segment [1] - The company is optimistic about the Phase II LANTIC trial data for its innovative long-acting molecule IPN10200 in the aesthetic medicine sector [1] Financial Performance - For the first nine months of 2025, the company achieved a year-on-year sales growth of approximately 10.0%, up from a previous expectation of over 7.0% [2] - The company has adjusted its full-year financial guidance based on strong performance metrics [2] Acquisition Details - The company signed a final equity acquisition agreement to acquire ImCheck Therapeutics, a French biotech firm focused on next-generation cancer immunotherapy [2] - The acquisition centers on the ICT01 project, which targets acute myeloid leukemia (AML) and is expected to enter Phase IIb/III trials in 2026 [2] - The deal includes an upfront cash payment of €350 million, with additional payments contingent on regulatory approvals and sales milestones [2]